Gastrointestinal Cancer | Topics

 
FOLFOX Plus Trastuzumab and Nivolumab Demonstrated Promising Efficacy in ERBB2+ Esophagogastric Adenocarcinoma
July 19, 2022

Patients with ERBB2-positive esophagogastric adenocarcinoma appeared to experience improved efficacy following treatment with a combination of trastuzumab and nivolumab plus leucovorin, fluorouracil, and oxaliplatin vs historical data.

A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction
July 18, 2022

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

FDA Delays Decision of Tislelizumab Monotherapy for Previously Treated Unresectable Advanced or Metastatic ESCC
July 14, 2022

The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.

Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial
July 13, 2022

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.

Platinum Hypersensitivity Reaction (HSR): An Ongoing Problem in Cancer Treatment
July 12, 2022

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.

Tislelizumab Plus Chemo Yields Survival Benefit Vs Chemo in Advanced ESCC
July 07, 2022

The phase 3 RATIONALE 306 trial showed improved overall survival for patients receiving tislelizumab plus chemotherapy vs placebo and chemotherapy for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status.

IMU-131 Plus SOC Improves OS Vs SOC Alone in Advanced/Metastatic Gastric or GEJ Cancer
June 28, 2022

Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.

68Ga-RM26 PET/CT Imaging Demonstrates Promise in Gastrointestinal Stromal Tumors
June 18, 2022

Patients with gastrointestinal stromal tumors may benefit from 68GA-RM26 PET/CT vs 18F-FDG, according to findings presented at the 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers
June 13, 2022

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

Dostarlimab Yields Clinical Complete Response in Entire Treated Population in dMMR Advanced Rectal Cancer
June 08, 2022

A 100% clinical complete response rate was observed when patients with stage II/III mismatch repair-deficient locally advanced rectal cancer were treated with dostarlimab.